Kisspeptin-10
KP-10 · Metastin fragment
An upstream reproductive-axis hormone studied in humans for libido and hormonal signalling.
Class
Kisspeptin (KISS1) receptor agonist
Half-life
Short (minutes)
Evidence
Limited human data
Limited human data
Small open-label studies, case series, or trials in a narrow population. Directionally informative, not conclusive.
Overview
Kisspeptin sits at the very top of the reproductive hormone cascade. It stimulates the hypothalamus to release GnRH, which drives LH and FSH, which in turn drive testosterone and estrogen production. Kisspeptin-10 is the shortest active fragment.
Imperial College London researchers have run genuine human studies showing kisspeptin administration enhances brain responses to sexual and emotional stimuli, boosts reproductive hormones, and may help men with low sexual desire — without the nausea and pressor effects of the melanocortin agonists.
Because it works upstream and physiologically, its effects are gentler and more hormonal than the on-demand melanocortin peptides. Its very short half-life is a practical limitation. It remains research-only, and community dosing is extrapolated from the research infusions.
How it works
- Agonises the kisspeptin receptor (KISS1R/GPR54) in the hypothalamus.
- Stimulates GnRH release, driving LH, FSH, and downstream sex hormone production.
- Enhances limbic-system responses to sexual and emotional stimuli in human brain-imaging studies.
- Works physiologically upstream, preserving natural hormonal rhythm.
What the research shows
Researched effects
- Enhanced brain responses to sexual/romantic stimuli in human fMRI studies
- Increased LH, FSH, and testosterone in human administration studies
- Improved sexual and mood responses in men with low desire (early trials)
- Cleaner side-effect profile than melanocortin agonists
Limitations & what it won't do
- Very short half-life; research used infusions or frequent dosing.
- Human evidence is early-stage and from research settings.
- Community dosing is extrapolated and inconsistent.
- Not FDA approved.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
Community protocol (research-extrapolated)
100–300 mcgThe short half-life means timing close to activity matters. Research studies used controlled IV infusions rather than subcutaneous dosing.
Reconstitution & measuring your dose
Handling
- Typical vial sizes
- 5 · 10 mg
- Suggested BAC water
- 2 mL
- Storage
- Lyophilised powder refrigerated at 2–8 °C, protected from light.
- After reconstitution
- Reconstituted: approximately 30 days refrigerated.
Why 2 mL? A 5 mg vial in 2 mL yields 2500 mcg/mL — 250 mcg lands on 10 units of a U-100 syringe.
Dose calculator
Draw to
2units
= 0.02 mL · 50 mcg per unit
Concentration
5000 mcg/mL
Doses per vial
100
Side effects
Common
- Injection-site irritation
- Generally well tolerated in studies
- Occasional mild flushing
Serious / rare
- Poorly characterised outside research settings
- Theoretical effects on the reproductive axis with heavy use
Contraindications & interactions
Do not use if you have
- Pregnant, breastfeeding, or trying to conceive
Acts on the reproductive axis; contraindicated in pregnancy.
- Active cancer or current oncology treatment
Hormone-sensitive cancers could be affected by sex-hormone stimulation. Avoid during active malignancy.
Use caution if you have
- Past cancer diagnosis (in remission)
For hormone-sensitive cancer history (breast, prostate), the sex-hormone stimulation warrants oncology clearance.
Medication interactions
- cautionTestosterone or anabolic therapy — Exogenous testosterone suppresses the axis kisspeptin stimulates — the two work against each other.
- monitorHormonal contraceptives / HRT — May interact with the hormonal axis contraceptives regulate.
What to monitor
- Sex hormone levels if used regularly
- Reproductive symptoms
Commonly combined with
References
- Comninos AN et al. — Kisspeptin modulates sexual and emotional brain processing in humansJournal of Clinical Investigation 2017;127:709-719
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if Kisspeptin-10 fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment